Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Plain-language summary
This Phase 1, Phase 2 trial is studying GW5282 combined with Golidocitinib, GW5282 combined with Golidocitinib, and other medications for people with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
GW5282 combined with Golidocitinib (DRUG): GW5282 and Golidocitinib will be administered in combination as twice daily (BID) and once daily (QD), respectively. The starting dose will be GW5282 40 mg BID combined with golidocitinib 150 mg QD. If tolerated, the dose of GW5282 will be subsequently escalated. | GW5282 combined with Golidocitinib (DRUG): GW5282 and Golidocitinib will be administered at the doses determined during escalation part. | Conventional CHOP regimen (DRUG): CHOP regimen includes the administrations of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
- Drugs / treatments
- GW5282 combined with Golidocitinib, GW5282 combined with Golidocitinib, Conventional CHOP regimen
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details